LipidDoc_ATL said:The mechanism and the magnitude are separate questions.
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
Dr.PeteFamMed said:ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…
Bookmarking. The distinction being drawn above is the one nobody else makes.
LipidDoc_ATL said:The mechanism and the magnitude are separate questions.
This is where I part company with the consensus forming above. I would resist the confidence. Half of what this board was certain about two years ago has since been quietly dropped, and nobody went back to correct the threads.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.
That is the short version; the long version is somebody else's post.